(Q35561366)

8 August 2017

1 reference

title

Management of hepatitis B and C in HIV co-infected patients (English)

1 reference

8 August 2017

Management of Hepatitis B and C in HIV Co-Infected Patients (English)

1 reference

https://api.crossref.org/works/10.1097/00126334-200309011-00009

22 March 2024

1 reference

Jürgen Kurt Rockstroh

1

1 reference

8 August 2017

language of work or name

English

0 references

publication date

1 September 2003

1 reference

Journal of Acquired Immune Deficiency Syndromes

8 August 2017

1 reference

8 August 2017

34 Suppl 1

1 reference

8 August 2017

S59-65

1 reference

Hepatitis B virus infection in the acquired immunodeficiency syndrome

8 August 2017

1

1 reference

https://api.crossref.org/works/10.1097/00126334-200309011-00009

Hepatitis C virus infection

22 March 2024

2

1 reference

https://api.crossref.org/works/10.1097/00126334-200309011-00009

More than third of world's population has been infected with hepatitis B virus

22 March 2024

3

1 reference

https://api.crossref.org/works/10.1097/00126334-200309011-00009

Relationship of hepatitis B virus infection to human immunodeficiency virus type 1 infection

22 March 2024

5

1 reference

https://api.crossref.org/works/10.1097/00126334-200309011-00009

The influence of human immunodeficiency virus type 1 infection on the development of the hepatitis B virus carrier state

22 March 2024

6

1 reference

https://api.crossref.org/works/10.1097/00126334-200309011-00009

Outcome of Hepatitis B Virus Infection in Homosexual Men and Its Relation to Prior Human Immunodeficiency Virus Infection

22 March 2024

7

1 reference

https://api.crossref.org/works/10.1097/00126334-200309011-00009

Perinatal transmission of hepatitis C virus from human immunodeficiency virus type 1-infected mothers. Women and Infants Transmission Study

22 March 2024

8

1 reference

https://api.crossref.org/works/10.1097/00126334-200309011-00009

Mother-to-infant transmission of hepatitis C virus. Lombardy Study Group on Vertical HCV Transmission

22 March 2024

9

1 reference

https://api.crossref.org/works/10.1097/00126334-200309011-00009

Infectiousness of HIV between male homosexual partners

22 March 2024

10

1 reference

https://api.crossref.org/works/10.1097/00126334-200309011-00009

Heterosexual transmission of hepatitis C virus and the possible role of coexistent human immunodeficiency virus infection in the index case. A multicentre study of 423 pairings

22 March 2024

11

1 reference

https://api.crossref.org/works/10.1097/00126334-200309011-00009

Does HIV infection favor the sexual transmission of hepatitis C?

22 March 2024

12

1 reference

https://api.crossref.org/works/10.1097/00126334-200309011-00009

Epidemiology of hepatitis C: geographic differences and temporal trends

22 March 2024

14

1 reference

https://api.crossref.org/works/10.1097/00126334-200309011-00009

Risk of needle-stick injuries in the transmission of hepatitis C virus in hospital personnel

22 March 2024

15

1 reference

https://api.crossref.org/works/10.1097/00126334-200309011-00009

The effect of concurrent human immunodeficiency virus infection on chronic hepatitis B: a study of 150 homosexual men.

22 March 2024

16

1 reference

https://api.crossref.org/works/10.1097/00126334-200309011-00009

Chronic hepatitis B in asymptomatic homosexual men with antibody to the human immunodeficiency virus

22 March 2024

17

1 reference

https://api.crossref.org/works/10.1097/00126334-200309011-00009

The interaction of human immunodeficiency virus infection and hepatitis B virus infection in infected homosexual men.

22 March 2024

18

1 reference

https://api.crossref.org/works/10.1097/00126334-200309011-00009

The influence of HTLV-III infection on the natural history of hepatitis B virus infection in male homosexual HBsAg carriers

22 March 2024

20

1 reference

https://api.crossref.org/works/10.1097/00126334-200309011-00009

Histological and immunohistochemical study of hepatitis B virus in human immunodeficiency virus infection

22 March 2024

21

1 reference

https://api.crossref.org/works/10.1097/00126334-200309011-00009

Effect of human immunodeficiency virus (HIV) infection on chronic hepatitis B hepatic viral antigen display

22 March 2024

22

1 reference

https://api.crossref.org/works/10.1097/00126334-200309011-00009

Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men.

22 March 2024

23

1 reference

https://api.crossref.org/works/10.1097/00126334-200309011-00009

Hepatitis B and C in HIV-infected patients. Prevalence and prognostic value

22 March 2024

24

1 reference

https://api.crossref.org/works/10.1097/00126334-200309011-00009

Hepatitis B in patients with HIV infection: relationship to AIDS and patient survival

22 March 2024

25

1 reference

https://api.crossref.org/works/10.1097/00126334-200309011-00009

Treatment of patients with chronic type B hepatitis and concurrent human immunodeficiency virus infection with a combination of interferon alpha and azidothymidine: a pilot study

22 March 2024

26

1 reference

https://api.crossref.org/works/10.1097/00126334-200309011-00009

Diminished responsiveness of male homosexual chronic hepatitis B virus carriers with HTLV-III antibodies to recombinant alpha-interferon

22 March 2024

27

1 reference

https://api.crossref.org/works/10.1097/00126334-200309011-00009

A preliminary trial of lamivudine for chronic hepatitis B infection

22 March 2024

29

1 reference

https://api.crossref.org/works/10.1097/00126334-200309011-00009

A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

22 March 2024

30

1 reference

https://api.crossref.org/works/10.1097/00126334-200309011-00009

Effects of lamivudine on replication of hepatitis B virus in HIV-infected men.

22 March 2024

31

1 reference

https://api.crossref.org/works/10.1097/00126334-200309011-00009

Dual efficacy of lamivudine treatment in human immunodeficiency virus/hepatitis B virus-coinfected persons in a randomized, controlled study (CAESAR). The CAESAR Coordinating Committee

22 March 2024

32

1 reference

https://api.crossref.org/works/10.1097/00126334-200309011-00009

Reactivation of hepatitis B in a long-term anti-HBs-positive patient with AIDS following lamivudine withdrawal

22 March 2024

33

1 reference

https://api.crossref.org/works/10.1097/00126334-200309011-00009

Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients

22 March 2024

34

1 reference

https://api.crossref.org/works/10.1097/00126334-200309011-00009

Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group

22 March 2024

35

1 reference

https://api.crossref.org/works/10.1097/00126334-200309011-00009

Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study

22 March 2024

36

1 reference

https://api.crossref.org/works/10.1097/00126334-200309011-00009

Increased risk of maternal-infant hepatitis C virus transmission for women coinfected with human immunodeficiency virus type 1. Italian Study Group for HCV Infection in Children

22 March 2024

37

1 reference

https://api.crossref.org/works/10.1097/00126334-200309011-00009

Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis

22 March 2024

40

1 reference

https://api.crossref.org/works/10.1097/00126334-200309011-00009

Influence of human immunodeficiency virus type 1 infection on the natural course of chronic parenterally acquired hepatitis C.

22 March 2024

41

1 reference

https://api.crossref.org/works/10.1097/00126334-200309011-00009

Hepatocellular carcinoma in HIV-infected patients with chronic hepatitis C

22 March 2024

42

1 reference

https://api.crossref.org/works/10.1097/00126334-200309011-00009

Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C. UK Haemophilia Centre Directors' Organisation

22 March 2024

43

1 reference

https://api.crossref.org/works/10.1097/00126334-200309011-00009

Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection

22 March 2024

45

1 reference

https://api.crossref.org/works/10.1097/00126334-200309011-00009

Mortality among human immunodeficiency virus-infected patients with cirrhosis or hepatocellular carcinoma due to hepatitis C virus in French Departments of Internal Medicine/Infectious Diseases, in 1995 and 1997.

22 March 2024

46

1 reference

https://api.crossref.org/works/10.1097/00126334-200309011-00009

Increasing impact of chronic viral hepatitis on hospital admissions and mortality among HIV-infected patients

22 March 2024

47

1 reference

https://api.crossref.org/works/10.1097/00126334-200309011-00009

Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study

22 March 2024

48

1 reference

https://api.crossref.org/works/10.1097/00126334-200309011-00009

Long-term efficacy of combination therapy with interferon-alpha 2b and ribavirin for severe chronic hepatitis C in HIV-infected patients

22 March 2024

49

1 reference

https://api.crossref.org/works/10.1097/00126334-200309011-00009

Interferon and ribavirin combination therapy for chronic hepatitis C in human immunodeficiency virus-infected patients with congenital coagulation disorders

22 March 2024

50

1 reference

https://api.crossref.org/works/10.1097/00126334-200309011-00009

Chronic hepatitis C in HIV infection: feasibility and sustained efficacy of therapy with interferon alfa-2b and tribavirin

22 March 2024

51

1 reference

https://api.crossref.org/works/10.1097/00126334-200309011-00009

22 March 2024

Molecular Pharmacology

52

38

766

Fernandez-Larsson

1990

1 reference

https://api.crossref.org/works/10.1097/00126334-200309011-00009

Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection

22 March 2024

54

1 reference

https://api.crossref.org/works/10.1097/00126334-200309011-00009

Mitochondrial toxic effects and ribavirin

22 March 2024

55

1 reference

https://api.crossref.org/works/10.1097/00126334-200309011-00009

Care of patients with chronic hepatitis C and HIV co-infection: recommendations from the HIV-HCV International Panel.

22 March 2024

56

1 reference

https://api.crossref.org/works/10.1097/00126334-200309011-00009

22 March 2024

Identifiers

1 reference

release_xu4ikkqk6fflbaqsk7semcgpou

8 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/xu4ikkqk6fflbaqsk7semcgpou

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference